We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
- Authors
Kyu Ha Huh; Jae Geun Lee; Jongwon Ha; Chang-Kwon Oh; Man Ki Ju; Chan-Duck Kim; Hong Rae Cho; Cheol Woong Jung; Beom Jin Lim; Yu Seun Kim
- Abstract
Background. Most of the previous studies reported that tacrolimus (TAC) with sirolimus (SRL) was associated with worse post-transplant outcomes in kidney transplantation, compared with TAC with mycophenolate mofetil (MMF). These might be attributable to high-dose SRL. However, outcomes using low-dose SRL with TAC for kidney transplantation are uncertain. The aim of this study was to assess the efficacy and safety of low-dose SRL with extended-release tacrolimus (ER-TAC) versus MMF with ER-TAC. Methods. We randomly assigned 158 renal transplant patients to receive low-dose SRL or MMF in combination with ER-TAC and corticosteroid. The primary endpoint was the composite efficacy failure rate, including biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up, within 12 months post-transplantation. This trial is registered with ClinicalTrial.gov (number NCT01680952). Results. The efficacy failure rate was 6.6% in the low-dose SRL group and 13.3% in the MMF group in the intention-to-treat population (absolute difference, 6.8%; 95% confidence interval, -2.8% to 16.3%). The incidence of BPAR within 12 months post-transplantation was 5.3% in the low-dose SRL group and 13.3% in the MMF group (P = 0.09). The mean estimated glomerular filtration rate at 12 months post-transplantation was 53.2 mL/min/1.73 m² in the low-dose SRL group and 52.4 mL/min/1.73 m² in the MMF group (P = 0.76). The incidences of adverse events and serious adverse events were similar between groups. Conclusion. Low-dose SRL with ER-TAC was not inferior to MMF with ER-TAC with respect to efficacy and safety. When used for immunosuppression in kidney transplantation, low-dose SRL with ER-TAC can effectively prevent acute rejection and preserve renal function.
- Subjects
RAPAMYCIN; MYCOPHENOLIC acid; TACROLIMUS; GLOMERULAR filtration rate; KIDNEY transplantation
- Publication
Nephrology Dialysis Transplantation, 2017, Vol 32, Issue 8, p1415
- ISSN
0931-0509
- Publication type
Academic Journal
- DOI
10.1093/ndt/gfx093